CMS adds flexibilities to final Aduhelm NCD, but usage could be rare
CMS’ final national coverage determination (NCD) on the Alzheimer’s drug Aduhelm may provide a clearer path to use, but critics warn the way CMS handled the approval issues could presage problems with other big-ticket drug decisions down the line.
To read the full article, sign in and subscribe to the DecisionHealth Newsletters.
Quick, Current, Complete - www.findacode.com